Evidence map›Paper›PMID 32504180›Full record

SynthesisJournal of neurology2021

Early diagnosis of secondary progressive multiple sclerosis: focus on fluid and neurophysiological biomarkers.

Gina Ferrazzano, Sebastiano Giuseppe Crisafulli, Viola Baione, Matteo Tartaglia, Antonio Cortese, Marco Frontoni, Marta Altieri, Flavia Pauri, Enrico Millefiorini, Antonella Conte

Registry-linked trialAbstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Journal of neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04997343 (Neurophysiological Estimates of Cortical Grey and White Matters Damage in Patients With Multiple Sclerosis), which is not on this map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04997343 naunknown statusnot on this map

Neurophysiological Estimates of Cortical Grey and White Matters Damage in Patients With Multiple Sclerosis

TypeinterventionalSponsorUniversity of Roma La SapienzaRan2021 to 2023Enrolled128ConditionsMultiple Sclerosis, Demyelinating Disease, Inflammatory DiseaseArmsNeurophysiological assessment, clinical assessment
3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Deciphering Multiple Sclerosis Progression.Frontiers in neurology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Gina FerrazzanoDepartment of Human Neurosciences, Sapienza University of Rome, Rome, Italy.
Sebastiano Giuseppe CrisafulliDepartment of Human Neurosciences, Sapienza University of Rome, Rome, Italy.
Viola BaioneDepartment of Human Neurosciences, Sapienza University of Rome, Rome, Italy.
Matteo TartagliaDepartment of Human Neurosciences, Sapienza University of Rome, Rome, Italy.
Antonio CorteseMultiple Sclerosis Center, San Filippo Neri Hospital, Rome, Italy.
Marco FrontoniDepartment of Human Neurosciences, Sapienza University of Rome, Rome, Italy.
Marta AltieriDepartment of Human Neurosciences, Sapienza University of Rome, Rome, Italy.
Flavia PauriDepartment of Human Neurosciences, Sapienza University of Rome, Rome, Italy.
Enrico MillefioriniDepartment of Human Neurosciences, Sapienza University of Rome, Rome, Italy.
Antonella ConteDepartment of Human Neurosciences, Sapienza University of Rome, Rome, Italy. antonella.conte@uniroma1.it.ORCID http://orcid.org/0000-0002-6338-2961

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsMost patients with multiple sclerosis presenting with a relapsing-remitting disease course at diagnosis transition to secondary progressive multiple sclerosis (SPMS) 1-2 decades after onset. SPMS is characterized by predominant neurodegeneration and atrophy. These pathogenic hallmarks result in unsatisfactory treatment response in SPMS patients. Therefore, early diagnosis of SPMS is necessary for prompt treatment decisions. The aim of this review was to assess neurophysiological and fluid biomarkers that have the potential to monitor disease progression and support early SPMS diagnosis.

methodsWe performed a systematic review of studies that analyzed the role of neurophysiological techniques and fluid biomarkers in supporting SPMS diagnosis using the preferred reporting items for systematic reviews and meta-analyses statement.

resultsFrom our initial search, we selected 24 relevant articles on neurophysiological biomarkers and 55 articles on fluid biomarkers.

conclusionTo date, no neurophysiological or fluid biomarker is sufficiently validated to support the early diagnosis of SPMS. Neurophysiological measurements, including short interval intracortical inhibition and somatosensory temporal discrimination threshold, and the neurofilament light chain fluid biomarker seem to be the most promising. Cross-sectional studies on an adequate number of patients followed by longitudinal studies are needed to confirm the diagnostic and prognostic value of these biomarkers. A combination of neurophysiological and fluid biomarkers may be more sensitive in detecting SPMS conversion.

Indexed as

Multiple SclerosisMultiple Sclerosis, Chronic ProgressiveMultiple Sclerosis, Relapsing-RemittingBiomarkersCross-Sectional StudiesDisease ProgressionEarly DiagnosisHumansBiomarkersBiomarkerEvoked potentialMicroRNANeurofilamentsNeurophysiologyProgressive multiple sclerosis

Identifiers

PMID32504180

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.